Home » Topics » BioWorld Science

BioWorld Science
RSS

Dynavax Technologies presents Toll-like receptor 7/8/9 antagonists

June 5, 2018

GERD candidate X-842 safe and well tolerated in first-in-human study

June 5, 2018

Cyxone chooses to complete acquisition of rabeximod

June 5, 2018

Myalepta receives positive CHMP opinion for generalized and partial lipodystrophy

June 5, 2018

Prelude Therapeutics identifies PRMT5 inhibitors

June 5, 2018

MALT1-targeting compounds synthesized by the Dana-Farber Cancer Institute and collaborators

June 5, 2018

Hepagene Therapeutics describes farnesoid X receptor agonists

June 5, 2018

GS-0976 demonstrates significant hepatic effects in patients with NASH cirrhosis

June 5, 2018

Bayer Animal Health discovers anthelmintic compounds

June 5, 2018

Mouse models of high-grade bladder cancer for in vivo evaluation of immunotherapy presented

June 5, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...